Non-coding RNA molecules including microRNAs and long non-coding RNAs (lncRNA) have been implicated in the pathogenesis of several tumors and numerous data support their applicability in diagnosis as well. Despite recent advances, the pathogenesis of adrenocortical cancer still remains elusive and there are no reliable blood-borne markers of adrenocortical malignancy, either. Several findings show the potential applicability of microRNAs as biomarkers of malignancy and prognosis, and there are some data on lncRNA as well. In this review, we present a synopsis on the potential relevance of non-coding RNA molecules in adrenocortical pathogenesis and their applicability in diagnosis from tissue and blood
Several lines of evidence support the relevance of microRNAs in both adrenocortical and adrenomedull...
miRNAs are short single-stranded non-coding RNAs which regulate gene expression at the posttranscri...
Adrenocortical cancer is a rare but very aggressive endocrine tumor, with a yearly incidence of 0.5 ...
Non-coding RNA molecules including microRNAs and long non-coding RNAs (lncRNA) have been implicated ...
Non-coding RNAs (ncRNAs) are a type of genetic material that do not encode proteins but regulate the...
Non-coding RNAs (ncRNAs) are a type of genetic material that do not encode proteins but regulate the...
Adrenocortical cancer (ACC) has a poor prognosis and limited treatments. Noncoding RNAs are importan...
International audienceAdrenocortical carcinoma (ACC) is a rare malignancy with poor prognosis and li...
International audienceMicroRNAs (miRNAs) are short non-coding RNAs that are involved in the epigenet...
Objective: To construct ceRNA network and identify pivotal competing endogenous RNAs (ceRNAs) in adr...
Differential diagnosis of adrenocortical adenoma (ACA) and carcinoma is of pivotal clinical relevanc...
Adrenocortical carcinoma (ACC) has high recurrence rates and poor prognosis with limited response to...
The histological differential diagnosis of adrenocortical adenoma and carcinoma is difficult and re...
Adrenocortical cancer (ACC) is a rare aggressive malignancy. Recent ACC integrated genomics analysis...
There is no available blood marker for the preoperative diagnosis of adrenocortical malignancy. The ...
Several lines of evidence support the relevance of microRNAs in both adrenocortical and adrenomedull...
miRNAs are short single-stranded non-coding RNAs which regulate gene expression at the posttranscri...
Adrenocortical cancer is a rare but very aggressive endocrine tumor, with a yearly incidence of 0.5 ...
Non-coding RNA molecules including microRNAs and long non-coding RNAs (lncRNA) have been implicated ...
Non-coding RNAs (ncRNAs) are a type of genetic material that do not encode proteins but regulate the...
Non-coding RNAs (ncRNAs) are a type of genetic material that do not encode proteins but regulate the...
Adrenocortical cancer (ACC) has a poor prognosis and limited treatments. Noncoding RNAs are importan...
International audienceAdrenocortical carcinoma (ACC) is a rare malignancy with poor prognosis and li...
International audienceMicroRNAs (miRNAs) are short non-coding RNAs that are involved in the epigenet...
Objective: To construct ceRNA network and identify pivotal competing endogenous RNAs (ceRNAs) in adr...
Differential diagnosis of adrenocortical adenoma (ACA) and carcinoma is of pivotal clinical relevanc...
Adrenocortical carcinoma (ACC) has high recurrence rates and poor prognosis with limited response to...
The histological differential diagnosis of adrenocortical adenoma and carcinoma is difficult and re...
Adrenocortical cancer (ACC) is a rare aggressive malignancy. Recent ACC integrated genomics analysis...
There is no available blood marker for the preoperative diagnosis of adrenocortical malignancy. The ...
Several lines of evidence support the relevance of microRNAs in both adrenocortical and adrenomedull...
miRNAs are short single-stranded non-coding RNAs which regulate gene expression at the posttranscri...
Adrenocortical cancer is a rare but very aggressive endocrine tumor, with a yearly incidence of 0.5 ...